SCYNEXIS INC — fact timeline

SCYNEXIS INC: Amended certificate of incorporation to effect a one-for-eight reverse stock split and reduce authorized shares from 150,000,000 to 18,750,000 (effective 2026-05-29).

“On May 28, 2026, SCYNEXIS, Inc., a Delaware corporation (the “Company”), filed with the Secretary of State of the State of Delaware a Certificate of Amendment to the Company’s Amended and Restated Certificate of Incorporation (the “Amendment”), to effect a one-for-eight (1:8) reverse stock split of its outstanding common stock (the “Reverse Stock Split”) and a reduction in the total number of authorized shares of its common stock from 150,000,000 to 18,750,000, effective as of May 29, 2026 (the “Share Reduction”).”

SCYNEXIS INC shareholders approved Approval of an amendment to the amended and restated certificate of incorporation, to implement a reverse stock split of the Company's common stock, at a ratio ranging from any whole number between 1-for-5 and 1-for-10, with such ratio to be determined at the discretion of the Board of Directors of at the 2026-05-19 meeting.

“Proposal 1: Approval of an amendment to the amended and restated certificate of incorporation, to implement a reverse stock split of the Company's common stock, at a ratio ranging from any whole number between 1-for-5 and 1-for-10, with such ratio to be determined at the discretion of the Board of Directors of the Company, and decrease the number of authorized shares. The votes were cast as follows: Votes For Votes Against Abstained 44,826,378 6,708,960 102,965”

SCYNEXIS INC issued 34,750,000 shares of common stock, 8,750,000 pre-funded warrants to purchase common stock, and 43,500,000 common warrants to purchase common stock (each common of unit to institutional and accredited investors including Great Point Partners, LLC, Squadron Capital Management LLC, Adage Capital Management, L.P., Propel Bio Partners, a large healthcare-dedicated fund, and David Angulo, the Company's President and CEO for Combined purchase price of $0.92 per common share and accompanying common warrant, and $0.9199 per pre-funded warrant and accompanying common warrant; total upf.

“Pursuant to the terms of the securities purchase agreement, the Company will issue an aggregate of (i) 34,750,000 shares of its common stock, $0.001 par value per share (the “Common Shares”), (ii) pre-funded warrants to purchase up to 8,750,000 shares of common stock (the “Pre-Funded Warrants”) and (iii) accompanying common warrants to purchase up to an aggregate 43,500,000 shares of common stock or pre-funded warrants in lieu thereof (the “Common Warrants”). The aggregate share issuance includes 108,695 Common Shares and accompanying Common Warrants that were sold to the Company’s President and Chief Executive Officer, Dr. David Angulo. Each Common Share (or Pre-Funded Warrant) will be accompanied by one Common Warrant. The Common Shares and accompanying Common Warrants were sold at a combined price of $0.92 per Common Share and accompanying Common Warrant, and 8,750,000 Pre-Funded Warrants and accompanying Common Warrants were sold at a combined price of $0.9199 per Pre-Funded Warran”

SCYNEXIS INC entered into Asset Purchase Agreement with Poxel SA valued at $8,000,000 (effective 2026-03-30).

“On March 30, 2026, SCYNEXIS, Inc. (the “Company”) and Poxel SA, a French corporation (“Poxel”), entered into an asset purchase agreement (the “Asset Purchase Agreement”)”

SCYNEXIS INC entered into Securities Purchase Agreement with certain new and existing institutional and accredited investors valued at approximately $40.0 million (effective 2026-03-30).

“On March 30, 2026, the Company entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain new and existing institutional and accredited investors (the “Investors”)”

SCYNEXIS INC received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).

“June 20, 2025, SCYNEXIS, Inc. (“SCYNEXIS”) received a letter from the Listing Qualifications Department staff (the “Staff”) of the Nasdaq Stock Market (“Nasdaq”) notifying SCYNEXIS that, for the last 30 consecutive business days, the closing bid price for SCYNEXIS’s common stock was below the $1.00 per share minimum required for continued listing on the Nasdaq Global Market as set forth in Nasdaq Listing Rule 5450(a)(1). The letter from Nasdaq has no immediate effect on the listing of SCYNEXIS’s common stock on the Nasdaq Global Market. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), SCY”

SCYNEXIS INC reported the year ended December 31, 2023 results: net income $67.0 million, EPS $1.40 basic income per share.

“Net income for the full year 2023, was $67.0 million, or $1.40 basic income per share”

SCYNEXIS INC amended Binding Memorandum of Understanding for Amendment to License Agreement with GlaxoSmithKline Intellectual Property (No. 3) Limited (effective 2023-12-26).

“On December 26, 2023, SCYNEXIS, Inc. (“SCYNEXIS”) and GlaxoSmithKline Intellectual Property (No. 3) Limited (“GSK”) entered into a binding memorandum of understanding (“Binding MOU”) for amendment to the exclusive license agreement between SCYNEXIS and GSK, dated March 30, 2023”

SCYNEXIS INC terminated Loan and Security Agreement with Hercules Capital, Inc. and Silicon Valley Bridge Bank, N.A. valued at $35 million (effective 2023-05-25).

“Item 1.02 Termination of a Material Definitive Agreement. SCYNEXIS, Hercules Capital, Inc. (“Hercules Capital”) and Silicon Valley Bridge Bank, N.A. (“SVB”) were party to a Loan and Security Agreement dated as of May 13, 2021 (the “Loan Agreement”), pursuant to which Hercules Capital, SVB and each of the other lenders from time-to-time party to the Loan and Security Agreement (collectively, the “Lenders”) loaned to SCYNEXIS $35 million.”

SCYNEXIS INC shareholders approved Approval of the SCYNEXIS, Inc. Amended and Restated 2014 Employee Stock Purchase Plan at the 2023-06-14 meeting.

“Proposal 6: The SCYNEXIS, Inc. Amended and Restated 2014 Employee Stock Purchase Plan was approved. The tabulation of votes on this matter was as follows: For Against Abstain Broker Non-Votes 15,588,230 1,474,343 179,242 9,302,100”

SCYNEXIS INC shareholders approved Approval of the SCYNEXIS, Inc. 2023 Equity Incentive Plan at the 2023-06-14 meeting.

“Proposal 5: The SCYNEXIS, Inc. 2023 Equity Incentive Plan was approved. The tabulation of votes on this matter was as follows: For Against Abstain Broker Non-Votes 9,751,905 7,212,033 277,877 9,302,100”

SCYNEXIS INC shareholders rejected Amendment to SCYNEXIS's Amended and Restated Certificate of Incorporation, as amended, to limit the liability of certain officers as permitted by Delaware General Corporation Law amendments at the 2023-06-14 meeting.

“Proposal 4: The amendment of the SCYNEXIS, Inc. Amended and Restated Certificate of Incorporation, as amended, to limit the liability of certain officers of SCYNEXIS as permitted pursuant to recent amendments to the Delaware General Corporation Law, as described in the Proxy Statement, was not approved, as this proposal required a vote of the majority of the shares outstanding (rather than simply a majority of the shares present and entitled to vote), which vote was not obtained (a total of 36,517,442 shares were outstanding on the record date). The tabulation of votes on this matter was as follows: For Against Abstain Broker Non-Votes 12,978,798 4,069,555 193,462 9,302,100”

SCYNEXIS INC shareholders approved Advisory approval of the compensation of SCYNEXIS's named executive officers as disclosed in the Proxy Statement at the 2023-06-14 meeting.

“Proposal 3: Advisory approval of the compensation of SCYNEXIS's named executive officers as disclosed in this Proxy Statement, was approved. The tabulation of votes on this matter was as follows: For Against Abstain Broker Non-Votes 13,038,648 3,868,468 334,699 9,302,100”

SCYNEXIS INC shareholders approved Ratification of appointment of Deloitte & Touche LLP as independent registered public accounting firm for fiscal year ending December 31, 2023 at the 2023-06-14 meeting.

“Proposal 2: The appointment of Deloitte & Touche LLP as SCYNEXIS’s independent registered public accounting firm for the fiscal year ending December 31, 2023, was ratified. The tabulation of votes on this matter was as follows: For Against Abstain Broker Non-Votes 25,161,193 1,133,817 248,905 —”

SCYNEXIS INC shareholders approved Election of seven directors proposed by SCYNEXIS for re-election at the 2023-06-14 meeting.

“Proposal 1: Each of the seven directors proposed by SCYNEXIS for re-election was elected to serve until SCYNEXIS’s 2024 Annual Meeting of Stockholders or until his or her respective successor has been elected and qualified. The tabulation of votes on this matter was as follows: For Withheld Broker Non-Votes David Angulo, M.D. 16,502,205 739,610 9,302,100 Armando Anido 16,015,447 1,226,368 9,302,100 Steven C. Gilman, Ph.D. 16,141,648 1,100,167 9,302,100 Ann F. Hanham, Ph.D. 16,267,526 974,289 9,302,100 David Hastings 14,175,218 3,066,597 9,302,100 Guy Macdonald 16,474,638 767,177 9,302,100 Philippe Tinmouth 16,493,678 748,137 9,302,100”

SCYNEXIS INC amended First Amendment and Consent to Loan and Security Agreement with Hercules Capital, Inc. and Silicon Valley Bridge Bank, N.A. valued at approximately $35.4 million.

“In connection with the entering into of the License Agreement, SCYNEXIS entered into a First Amendment and Consent to Loan and Security Agreement with the Lenders pursuant to which the Lenders consented to SCYNEXIS entering into the License Agreement and SCYNEXIS agreed to pay to the Lenders an amount equal to the sum of (i) all outstanding principal plus all accrued and unpaid interest with respect to the amounts loaned under the Loan Agreement (approximately $35.4 million), (ii) the prepayment fee payable under Loan Agreement ($262,500), (iii) the final payment payable under Loan Agreement ($1,382,500), and (iv) all other sums, if any, that shall have become due and payable with respect to loan advances under the Loan Agreement.”

SCYNEXIS INC entered into License Agreement with GlaxoSmithKline Intellectual Property (No. 3) Limited (GSK) valued at $90 million (effective 2023-03-30).

“On March 30, 2023 SCYNEXIS, Inc. entered into a license agreement (the “License Agreement”) with GlaxoSmithKline Intellectual Property (No. 3) Limited (“GSK”).”

SCYNEXIS INC reported the third quarter ended September 30, 2022 results: revenue $1.6 million.

“the Board effective January 1, 2023. • BREXAFEMME ® (ibrexafungerp tablets) prescriptions continued to grow in Q3 2022, increasing 13% over Q2 2022, generating net revenues of $1.6 million in Q3 2022, compared to $1.3 million in Q2 2022. • Coverage for BREXAFEMME increased to 130 million, or 70% of commercially insured lives, with the addition of a major national”

Ivor Macleod was appointed as Chief Financial Officer at SCYNEXIS INC.

“On October 20, 2022, SCYNEXIS announced that Ivor Macleod, CPA, MBA, will become SCYNEXIS’s Chief Financial Officer, in which role he will become SCYNEXIS’s principal financial officer and principal accounting officer. Mr. Macleod’s anticipated first date of employment is October 24, 2022.”

David Angulo changed role as President and Chief Executive Officer at SCYNEXIS INC.

“On October 20, 2022, SCYNEXIS announced that David Angulo, M.D., SCYNEXIS’s Chief Medical Officer, will become SCYNEXIS’s President and Chief Executive Officer and become a member of the Board of Directors effective January 1, 2023.”

Marco Taglietti departed as President and Chief Executive Officer at SCYNEXIS INC.

“On October 14, 2022, Dr. Marco Taglietti announced to SCYNEXIS, Inc. that he plans to retire and will leave his position as President and Chief Executive Officer of SCYNEXIS, and will step down from the SCYNEXIS Board of Directors, on December 31, 2022.”

Lawrence Hoffman was appointed as interim Chief Financial Officer at SCYNEXIS INC.

“On November 1, 2021, the Board of Directors of SCYNEXIS appointed Lawrence Hoffman, CPA, ESQ, of Danforth Advisors, LLC (“Danforth”) as interim Chief Financial Officer, effective as of the Transition Date.”

Eric Francois resigned as Chief Financial Officer at SCYNEXIS INC.

“As previously announced, Eric Francois, Chief Financial Officer of SCYNEXIS, Inc. (the “Company”), will resign to return to his prior career in investment banking.”

Eric Francois resigned as Chief Financial Officer at SCYNEXIS INC.

“On October 26, 2021, Eric Francois, Chief Financial Officer of SCYNEXIS, Inc. (the “Company”), notified the Company of his intent to resign to return to his prior career in investment banking.”